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Abstract
The cyclical and heterogeneous nature of many substance use disorders highlights the need to adapt
the type or the dose of treatment to accommodate the specific and changing needs of individuals. The
Adaptive Treatment for Alcohol and Cocaine Dependence study (ENGAGE) is a multi-stage randomized
trial that aimed to provide longitudinal data for constructing treatment strategies to improve patients’
engagement in therapy. However, the high rate of noncompliance and lack of analytic tools to account
for noncompliance have impeded researchers from using the data to achieve the main goal of the trial.
We overcome this issue by defining our target parameter as the mean outcome under different treatment
strategies for given potential compliance strata and propose a Bayesian semiparametric model to estimate
this quantity. While it adds substantial complexities to the analysis, one important feature of our work
is that we consider partial rather than binary compliance classes which is more relevant in longitudinal
studies. We assess the performance of our method through comprehensive simulation studies. We
illustrate its application on the ENGAGE study and demonstrate that the optimal treatment strategy
depends on compliance strata.
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Sequential multiple assignment randomized trial.
1 Introduction
The cyclical and heterogeneous nature of substance use disorders highlights the need to tailor the type and/or
the dose of treatment to the specific and changing needs of individuals (McKay, 2009; Kranzler & McKay,
2012; Black & Chung, 2014; Witkiewitz et al., 2015). One important feature of substance use disorders
research that makes constructing effective treatment regimes challenging is the high rate of noncompliance
(≥ 50%) to treatments. In general, failing to properly adjust for noncompliance can limit the usefulness and
generalizability of the results.
A dynamic treatment regime is a treatment design that seeks to accommodate patient heterogeneity in
response to treatments (Murphy et al., 2001; Murphy, 2003; Robins, 2004; Chakraborty & Moodie, 2013;
Chakraborty & Murphy, 2014; Laber et al., 2014). In dynamic treatment regimes, the type and/or dose of
the treatment is adapted over time according to the patient’s characteristics and progress in treatment. The
optimal dynamic treatment regime is one that optimizes the expected health outcome of interest. Recently,
there has been increased interest in sequential, multiple assignment, randomized trials (SMARTs), which
were specifically developed to provide empirical evidence for the construction of optimal dynamic treatment
regimes. The SMART is a clinical trial design in which the randomization scheme takes into account patient
response to prior treatments (Lavori et al., 2000; Murphy, 2005; Lei et al., 2012; Nahum-Shani et al., 2012;
Chakraborty & Moodie, 2013). Several sequences of treatments of scientific interest are embedded in a
SMART to form the embedded dynamic treatment regimes. These often use a single tailoring variable, such
as the individuals’ early response status.
Existing methods for analyzing SMART data are limited to intention-to-treat analyses. Intention-to-treat
analysis measures the effect of randomization to a particular group on the outcome regardless of whether
the individual complied with their assigned treatment. There are two main criticisms of intention-to-treat
analyses: 1) the treatment effect estimates are biased due to confounding; the bias is often toward the null
hypothesis of no effect because the estimate occurs across individuals with different levels of compliance
(Marasinghe & Amarasinghe, 2007; Lin et al., 2008). In fact, the intention-to-treat effect estimate will
likely diminish as noncompliance increases; 2) the rate of compliance or the compliance pattern in standard
clinical practice may not be the same as the rate or the pattern in the clinical trial (Frangakis & Rubin, 1999;
Robins & Tsiatis, 1991; Hewitt et al., 2006). These two shortcomings can seriously limit the usefulness and
generalizability of the concluding results. Noncompliance rates are particularly high in substance use disorder
treatment (US Department of Health and Human Services and others, 1992). This is a major challenge for
the Adaptive Treatment for Alcohol and Cocaine Dependence (ENGAGE) study, which attempts to deliver
new interventions to patients who have failed in the first treatment administered and therefore are at risk to
either not initiate the new intervention or to drop out quickly (McKay et al., 2015; Van Horn et al., 2015).
1.1 Accounting for noncompliance
An important challenge in adjusting for compliance is that observed compliances are post-treatment variables.
Therefore, conditioning on them may induce the post-treatment adjustment bias. To overcome this issue,
instrumental variable and principal stratification based methods have been proposed. Instrumental variable
analyses are widely used to adjust for binary compliances in two-arm randomized trials. In this case,
treatment assignment may be used as an instrument to obtain an unbiased estimate of the treatment effect
for compliers where compliers are the subgroup of patients who would receive the treatment that matches
the instrumental variable regardless of the instrumental variable’s value (Angrist & Imbens, 1995; Angrist
et al., 1996; Angrist, 2006; Wooldridge, 2010; Wooldridge, 2015; Ertefaie et al., 2018).
In the context of individualized medicine, Cui & Tchetgen Tchetgen (2019) developed a semiparametric
approach to account for noncompliance. In particular, they provide a method for non-parametric identifi-
cation of the optimal treatment strategy among compliers for a single-stage trial in the presence of binary
noncompliance. However, in longitudinal studies, compliance is often defined as the average compliance
measured through the follow-up time which is a continuous variable. In this case, in order to use instru-
mental variable based approaches with a binary instrument, the partial compliance must be thresholded to
form a binary compliance variable. This procedure has two shortcomings: (1) the results may depend on
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the threshold used for dichotomization; and (2) it leads to loss of information in compliance behaviour due
to the dichotomization.
Principal stratification provides an alternative framework to account for noncompliance (Efron & Feld-
man, 1991; Frangakis & Rubin, 2002; Frangakis et al., 2002; Greevy et al., 2004). Jin & Rubin (2008)
employed a Bayesian approach to principal stratification by modeling partial potential compliances using
the beta distribution. Their method relies on a monotonicity assumption which states placebo compliance is
always higher than treatment compliance. This assumption may not be reasonable for randomized clinical
trials with two active arms where there is not a clear ordering of potential compliances. Moreover, their
method does not allow modeling complicated distributions of compliance for which the beta distribution is
a poor fit. Schwartz et al. (2011) proposed an alternative Bayesian semiparametric framework to relax some
of the restrictive assumptions made in Jin & Rubin (2008). Specifically, Schwartz et al. (2011) estimated the
joint distribution of the potential compliances non-parametrically using a Dirichlet process (DP) mixture
and data augmentation to impute the latent potential compliances (Kim et al., 2019a,b). The use of a DP
mixture for kernel density estimation allows complicated distributions of compliance to be modeled giving
it an advantage over other methods by relaxing the parametric assumptions made in Jin & Rubin (2008). It
furthermore clusters individuals which allows information to be shared between observations within clusters
aiding in estimation of the joint potential compliance distribution. Frequentist approaches have also been
explored to account for partial compliance in randomized clinical trials. Bartolucci & Grilli (2011) proposed
a principal stratification based method where the joint distribution of potential compliances were modeled
using a Plackett copula. This approach has the disadvantage of empirical findings depending on the choice
of a sensitivity parameter specifying association in the Plackett copula. The existing methods, focus entirely
on single time point treatment assignment settings and are not applicable to SMARTs. Our method fills
this gap.
1.2 Our contribution
We propose a method to estimate the mean outcome under a given treatment strategy in the presence of
partial compliance. We leverage principal stratification in which strata are formed by potential compliances.
The potential compliance of a particular treatment is the compliance that would have been observed, had
the patient been assigned to that treatment. These are pre-treatment patient characteristics; hence, they
may be treated as baseline covariates. We refer to the principal strata as compliances classes. An important
challenge with principal stratification is that some of the potential compliances are latent.
We propose a Bayesian semiparametric approach for estimating the mean treatment strategy outcome
given compliance classes. A crucial step for identifiability of our target parameter is to estimate the joint
distribution of the potential compliances which is used to augment the unobserved potential compliances. To
reduce the chance of model misspecification, we estimate the joint distribution non-parametrically using a
Dirichlet process mixture. The method accounts for treatment effect heterogeneity with respect to patient’s
compliance behavior, which in turn leads to finding optimal dynamic treatment regimes that better suit
the patients’ needs/desires and boosts the interpretability of the results. The proposed method builds upon
Schwartz et al. (2011) and extends the existing principal stratification methods from single-stage to multi-
stage treatment decision settings. Furthermore, for a given compliance class, we determine which dynamic
treatment regimes are indistinguishable from the optimal dynamic treatment regime within a class of regimes
using multiple comparisons with the best (MCB) (Hsu, 1981, 1996). The best refers to the embedded DTR
which maximizes some health outcome. MCB adjusts for multiple comparisons and yields greater power
compared with methods which entail all pairwise comparisons (Ertefaie et al., 2015; Artman et al., 2018).
The interpretation of the set of best dynamic treatment regimes is appealing to investigators as it sheds
light on how the optimal dynamic treatment regimes change depending on compliance class while taking
into account the uncertainty of each dynamic treatment regime outcome.
1.3 Outline
In Section 2, we summarize the ENGAGE SMART. In Section 3, we introduce our framework including
notation, the estimand, and the likelihood. Next, in Section 4, we present the non-parametric Bayesian
model for partial compliance in full generality. Afterward, we describe the estimation and inference procedure
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Figure 1: Diagram of the ENGAGE SMART.
using a Gibbs sampler in Section 5. In Section 6, we present our assumptions in full generality as well as
for the two SMART examples. In this Section, we present a theorem which proves identifiability of the
regression coefficients in the outcome-potential compliance model subject to our assumptions. After we
finish discussing estimation of the embedded DTRs, we transition to Section 7, where we discuss model
selection. We subsequently summarize multiple comparisons with the best in Section 8 which is a procedure
for comparing embedded DTRs. After we fully describe our methodology, we examine the performance of
our method using extensive simulation studies in Section 9. In Section 10, we then apply our method to
the real ENGAGE SMART study. Lastly, we conclude with a discussion in Section 11. Omitted proofs and
figures can be found in the Appendix.
2 ENGAGE SMART study
The subjects in the Adaptive Treatment for Alcohol and Cocaine Dependence (ENGAGE) study were pa-
tients who abuse alcohol and patients who abuse cocaine (McKay et al., 2015; Van Horn et al., 2015). The
primary goal of the ENGAGE study was to determine the effect of permitting patients who failed to en-
gage in or dropped out of intensive outpatient programs (IOPs) to choose their subsequent treatment. The
study initially followed patients who were in IOP. After 2 weeks, those who failed to engage in IOP were
randomized to one of two motivational interviewing (MI) interventions. Non-engagement was defined as
failing to attend two or more IOP session in Week 2. The first intervention encouraged patients to engage in
IOP (MI-IOP). The second offered patients a choice for treatment (called patient choice or MI-PC). For our
analysis, we consider the study from the 2 week point where patients were first randomized. PC consisted
of choosing from cognitive behavioral therapy, telephone-based stepped care, IOP, or medical management.
After 8 weeks, subjects who failed to engage in IOP (defined as not attending any IOP sessions in Weeks 7
and 8) were re-randomized to either MI+PC or no further outreach care (NFC). See Figure 1 for a diagram
depicting the SMART. Note that not-engaging is related to, but not the same as not complying. Compliance
is the fraction of sessions attended while engaging is meeting certain criterion defined in the study which is
used as a tailoring variable.
In this study, there were three potential compliances corresponding to MI-IOP stage 1, MI-PC stage 1,
and MI-PC stage 2. There were 4 embedded DTRs. Two of the embedded DTRs were as follows:
1. Start with MI+IOP. If the subject is engaged during the first 8 weeks, then at the 8-week point, offer
NFC; if the subject is labeled as a non-engager at week 8 of follow-up, offer MI+PC.
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Figure 2: Diagram of the General SMART.
2. Start with MI+IOP. If the subject is engaged during the first 8 weeks, then at the 8-week point, offer
NFC; if the subject is labeled as a non-engager at week 8 of follow-up, offer NFC.
The other two embedded DTRs are similar (see Table 1). See McKay et al. (2015); Van Horn et al. (2015)
for more details about the SMART.
Figure 3 shows the low overall compliance in the ENGAGE study emphasizing the importance of incor-
porating compliance information when comparing embedded DTRs. Figure 4 shows the distribution of the
observed compliance for non-responders to stage-1 treatment MI-IOP on the left and MI-PC on the right.
Stage-2 compliance to MI-PC is overlayed. Note that the compliance for stage-2 is substantially lower than
that of stage-1 treatments. This is what one might expect since stage-2 subjects are non-engagers and hence
low compliers. The stage-1 treatment observed compliances for MI-IOP and MI-PC are similar; however,
there is more weight near 100% for MI-IOP compared with MI-PC stage-1.
Determination of optimal embedded DTR in ENGAGE would inform physicians about whether permit-
ting patients to choose their care is superior to allowing physicians to choose subsequent care. The outcome
included measures of alcohol and cocaine use between week 2 and 24. We define partial compliance as the
fraction of sessions attended for an intervention. One might expect that compliance is lower when physi-
cians choose leading to poorer outcomes. By allowing patients choice of care, outcomes may be improved
as compliance will be higher. However, if a patient is known a priori to be a high complier, the physician’s
assignment may be superior to patient’s choice due to greater subject matter knowledge of the physician
compared with the patient.
In Figure 5, we plot the log of the cumulative number of days of drinking alcohol and using cocaine vs.
observed compliances for each of the six treatment sequences in ENGAGE shown in Figure 1. Higher values
imply poorer outcomes. We see a negative trend for all groups except for the sequence Stage-1 MI-PC,
non-responder, stage-2 MI-PC. The top marginal density plot shows that observed compliance is higher for
MI-PC which makes sense as patients get to choose their intervention. The interpretation of Figure 5 should
be taken with care as the compliances are observed rather than potential.
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3 Framework
3.1 Notation
We develop our method under a more general SMART structure than the ENGAGE study by allowing both
responders and non-responders to stage-1 interventions to be re-randomized at the second stage (Figure 2).
Let A1 ∈ {−1,+1} be the stage-1 treatment indicator, AR2 ∈ {−1,+1} be the stage-2 treatment indicator
for responders to the stage-1 treatment, and ANR2 ∈ {−1,+1} be the stage-2 treatment indicator for non-
responders to the stage-1 treatment. Let D11i denote the stage-1 potential compliance for subject i had
they been randomized to A1i = +1 and D12i denote the stage-1 potential compliance for subject i had
they been randomized to A1i = −1. Similarly, define DR2j and DNR2j as the jth (j = 1, 2) stage-2 potential
compliances for responders and non-responders to stage-1 treatment, respectively. We assume that the
partial compliances take their value in R[0,1] (i.e., (D11, D12, DR21, DR22, DNR21 , DNR22 ) ∈ [0, 1]6). Let Si denote
the observed stage-1 treatment response indicator for subject i. Let Yik, k = 1, ...,K denote the potential
outcome of the kth treatment sequence at the end of the study for subject i. Let Y
(l)
i , l = 1, ..., L denote
the potential outcome of the lth embedded DTR for subject i. In ENGAGE, K = 6 and L = 4 while in the
general SMART (Figure 2), K = L = 8. Let n be the total sample size in the SMART.
The general SMART includes 8 embedded dynamic treatment regimes listed in Table 2. There are a total
of 6 possible potential compliances: two for stage 1 (D11, D12); two for responders to stage-1 treatments
(DR21, D
R
22); and two for non-responders to stage-1 treatments (D
NR
21 , D
NR
22 ). Because, the first stage-2 inter-
vention option for responders is the same intervention as for stage 1, it is plausible to assume that DR21 = D11.
This reduces the number of potential compliances to 5 (i.e., D11, D12, D
R
22, D
NR
21 , D
NR
22 ). In the ENGAGE
study, because there is no re-randomization among responders, the potential compliances DR21 and D
R
22 do
not exist. Moreover, in ENGAGE, non-responders were re-randomized to a placebo (i.e., NFC) and an active
intervention which reduces the number of potential compliances among non-responders. Specifically, because
patients assigned to NFC do not have access to the other treatment option the only potential compliance for
non-responders is DNR22 . Thus, in the ENGAGE study, there are only three potential compliances: D11, D12,
and D22(≡ DNR22 ).
3.2 Estimand
The estimand of interest is the average outcome for a particular embedded DTR Y
(l)
i , in a compliance class
specified by D. These are known as the principal causal effects and are defined as PCE(l)(D) = E[Y (l) |D],
for l = 1, 2, · · · , L where L is the number of embedded DTRs.
In the SMART setting, the principal causal effects can also be represented as
PCE(l)(D) = E[Y | A1 = a1l,S = 1, AR2 = a2l,D] Pr(S = 1 | A1 = a1l,D)+
E[Y | A1 = a1l, S = 0, ANR2 = a2l,D] Pr(S = 0 | A1 = a1l,D), l = 1, 2, · · · , L,
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Figure 4: Non-responder compliance density plots for each stage.
where Y is the observed outcome and ajl is the treatment option at stage j (j = 1, 2) that is consistent with
the lth embedded DTR (see Appendix A). Although, for illustrative purposes, we only focus on unconditional
principal causal effects (i.e., averaged over the baseline covariates), the proposed methods can be readily
applied to principal causal effects conditional on baseline covariates as well. The main challenge in estimating
the principal causal effects is that the compliance classes are partially latent. We propose a method to
impute the missing potential compliances leveraging a Bayesian non-parametric model and a parametric
outcome model. The procedure is presented in the next section. We now describe how to leverage the PCE
representation with Markov Chain Monte Carlo.
Let θ(D)(l) = E[Y (l) | D], θR(D) = E[Y | A1 = a1l, S = 1, AR2 = a2l,D], θNR(D) = E[Y | A1 =
a1l, S = 0, A
NR
2 = a2l,D], and λA1(D) = Pr(S = 1 | A1 = a1l,D). Given a vector of augmented potential
compliances D, at the mth iteration of the Gibbs sampler, we draw θ
(m)
R (D), θ
(m)
NR (D), and λ
(m)
A1
(D). Hence,
the mth draw of the principal causal effect is
θ(D)(l),(m) = θR(D)
(m)λ
(m)
A1
(D) + θ
(m)
NR (D)(1− λ(m)A1 (D))
Then, by the law of large numbers, E[Y (l) | D] ≈ 1
M
∑M
m=1 θ(D)
(l),(m). Throughout, we fit the condi-
tional means, θR(D)
(m), using Bayesian linear regression and the probability of response, λ
(m)
A1
(D), using
Bayesian logistic regression.
We now describe the complete-data likelihood. Assume i.i.d. observations. Define θ as the vector of
parameters. We have that the complete-data likelihood is as follows:
Pr(Y obs,D,Sobs,A1,A2 | θ)
∝
n∏
i=1
Pr(Y obsi ,Di, S
obs
i , A1i, A2i | θ)
∝
n∏
i=1
Pr(Y obsi |Di, Sobsi , A1i, A2i,θ) Pr(Sobsi |Di, A1i,θ) Pr(Di | θ)
7
Embedded Dynamic Treatment Regime
1 A1 = +1, S = 1 or A1 = +1, S = 0, A2 = +1
Receive MI-IOP, if respond receive NFC, if not respond switch to MI-PC
2 A1 = +1, S = 1 or A1 = +1, S = 0, A2 = −1
Receive MI-IOP, if respond, receive NFC, if not respond, receive NFC
3 A1 = −1, S = 1 or A1 = −1, S = 0, A2 = +1
Receive MI-PC, if respond receive NFC, if not respond switch to MI-PC
4 A1 = −1, S = 1 or A1 = −1, S = 0, A2 = −1
Receive MI-PC, if respond receive NFC, if not respond, receive NFC.
Table 1: Embedded dynamic treatment regime decision rules for the ENGAGE SMART.
4 Non-parametric Bayesian model for potential compliances
In this section we specify the Dirichlet process (DP) mixture model to estimate non-parametrically the
joint distribution of the potential compliances. Consider the DP with base measure G0 and concentration
parameter α which specifies the sparsity of a discrete realization of the DP. The realization of a DP is itself a
distribution. A random measure G ∼ DP(αG0) may be constructed using the stick-breaking representation
(Schwartz et al., 2011):
G(·) =
∞∑
h=1
whδγh(·) and γh
iid∼ G0,
wh = w
′
h
∏
k<h
(1− w′k) and w′h iid∼ Beta(1, α).
where δγ(·) is a point mass at γ. The joint distribution of the potential compliances is estimated as follows:
fD(d | γ) =
∫
K(d | γ)dG(γ) (1)
where G ∼ DP(αG0) and K(· | γ) is a kernel. Compliances are between 0 and 1 so we use the multivariate
truncated normal distribution restricted to the unit (hyper)cube [0, 1]m as a kernel where m is the number
of potential compliances. Then, (1) is equivalent to
fD(d | {γh}) =
∞∑
h=1
whchN (d | ηh,Σh) 1[0,1]m (2)
where γh = {ηh,Σh} are the pre-truncation means and the pre-truncation covariances in the hth mixture
component and ch is a normalizing constant for the h
th multivariate truncated normal distribution and is a
function of Σh and ηh. The indicator variable 1[0,1]m implies truncation to the interval [0, 1]
m.
To facilitate Bayesian inference, approximate (2) with the sum of the first H terms. Then,
fD(d | {γh}) ≈
H∑
h=1
whchN (d | ηh,Σh) 1[0,1]m ,
where γh = {ηh,Σh}. Next, define latent mixture component indicators Zi specifying to which of the H
components subject i belongs. Then, Zi is categorically distributed meaning
Pr(Zi = h) =
H∏
h=1
p
1(Zi=h)
h where
∑
h
ph = 1.
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Figure 5: Log of the cumulative number of days of consuming alcohol and cocaine vs. observed compliance
with marginal densities.
and
fD(di | Zi = h,γh) = chN (di | ηh,Σh) 1[0,1]m .
The constant H can be determined by running a preliminary Gibbs sampler with a large number of
components. Then, observe what is the highest mixture component indicator value, and choose H such that
it is higher than the number of DP clusters. We now describe how to draw the weights. Conditional on Z,
for all h ∈ {1, ...,H − 1}, the posterior of the w′h’s from the stick-breaking representation are:
f(w′h | α,Z) = Beta
(
w′h | 1 +
n∑
i=1
1(Zi = h), α+
n∑
i=1
1(Zi > h)
)
.
Set w′H = 1 and the mixture weights to wh = w
′
h
∏
k<h(1− w′k). Subsequently, assuming the prior f(α) for
the concentration parameter α, the posterior is
f(α | Z,w′) ∝ f(α)
H∏
h=1
Beta
(
w′h | 1 +
n∑
i=1
1(Zi = h), α+
n∑
i=1
1(Zi > h)
)
.
By the specification of the joint distribution of potential compliances, the posterior for the mixture component
9
Embedded Dynamic Treatment Regime
1 A1 = +1, S = 1, A
R
2 = +1 or A1 = +1, S = 0, A
NR
2 = +1
Receive Trt. 1, if respond, continue trt 1, if not respond, switch to trt 4.
2 A1 = +1, S = 1, A
R
2 = +1 or A1 = +1, S = 0, A
NR
2 = −1
Receive Trt. 1, if respond continue Trt 1, if not respond, add trt. 4
3 A1 = +1, S = 1, A
R
2 = −1 or A1 = +1, S = 0, ANR2 = +1
Receive trt 1, if respond add trt 3, if not respond switch to trt 4
4 A1 = +1, S = 1, A
R
2 = −1 or A1 = +1, S = 0, ANR2 = −1
Receive Trt. 1, if respond add Trt 3., if not respond add trt. 4.
5 A1 = −1, S = 1, AR2 = +1 or A1 = −1, S = 0, ANR2 = +1
Receive trt.2, if respond continue trt. 2., if no respond switch to trt 4.
6 A1 = −1, S = 1, AR2 = +1 or A1 = −1, S = 0, ANR2 = −1
Receive trt. 2, if respond, continue trt. 2, if not respond, add trt 4.
7 A1 = −1, S = 1, AR2 = −1 or A1 = −1, S = 0, ANR2 = +1
Receive trt.2, if respond add trt. 3, if not respond switch to trt 4.
8 A1 = −1, S = 1, AR2 = −1 or A1 = −1, S = 0, ANR2 = −1
Receive trt. 2, if respond add trt. 3., if not respond, add trt 4.
Table 2: Embedded dynamic treatment regime decision rules for the General SMART.
indicator is:
Pr(Zi = h |Di = di,γh) ∝ fD(di | Zi = h,γh) Pr(Zi = h)
∝ whchN (di | ηh,Σh) 1[0,1]m .
Individuals with characteristics which are most consistent with the hth mixture component will have Z = h
with high probability. This demonstrates the clustering property of the Dirichlet process mixture. Assume
that the Dirichlet process base measure G0 has first component which is flat and second component which
is Inverse-Wishart. Then, the posterior of the pre-truncation means ηh are:
f(ηh |Di : Zi = h,Σh,Z) ∝
∏
i:Zi=h
N (Di | ηh,Σh)∫ 1
0
N (x | ηh,Σh)dx
.
The posterior for the pre-truncation covariance Σh are:
f(Σh |Di : Zi = h,ηh,Z) ∝ IW(Σh | m, Im)
∏
i:Zi=h
N (Di | ηh,Σh)∫ 1
0
N (x | ηh,Σh)dx
.
5 Gibbs sampler
Posterior inference is carried out using a Gibbs sampler. First, draw the missing potential compliances for
each individual. Then, draw the parameters from the conditional posteriors at each step and iterate. Since
the posteriors of α, Σh, and ηh do not have a closed form of a known distribution, Metropolis-Hastings steps
are taken within the Gibbs sampler at each iteration.
1. Fix H, the number of DP mixture components.
2. Draw Dmisi , i = 1, ..., n, from the conditional posterior f(D
mis
i | Dobsi , Yi,β, σ2, Zi = h,γh). The
expression for the posterior may be derived using facts about the conditional distribution of multivariate
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normal distribution. In particular, the conditional posterior density is given by the following:
f(Dmisi |Dobsi , Yi,β, σ2, Zi = h,γh) ∝ f(Yi |Di,β, σ2, Zi = h,γh)f(Dmisi |Dobsi , Zi = h,γh)
∝ N (Yi |D>i β, σ2)N (Dmisi |Dobsi ,γh, Zi = h)1[0,1]m .
Note that the product of the normal density and truncated normal density will also be truncated
normal and depend on Yi.
3. Draw ηh, h = 1, ...,H, from their conditional posteriors f(ηh | Di : Zi = h,γh) using a Metropolis-
Hastings step:
(a) Propose a point ηproph ∼ N (D¯h, n−1h Σh) and accept with probability
αηh = min
(
1,
f(ηproph |Di : Zi = h,Σh)f(ηcurrenth | D¯h, n−1h Σh)
f(ηcurrenth |Di : Zi = h,Σh)f(ηproph | D¯h, n−1h Σh)
)
.
4. Draw Σh, h = 1, ...,H, from their conditional posterior f(Σh | Di : Zi = h,ηh) using a Metropolis-
Hastings step:
(a) Propose a point Σproph ∼Wishart(1000,Σcurrenth /1000) and accept with probability:
αΣh = min
(
1,
f(Σproph |Di : Zi = h,ηh)fWishart(Σcurrenth | Σproph )
f(Σcurrenth |Di : Zi = h,ηh)fWishart(Σproph | Σcurrenth )
)
.
5. Given w and Di, draw Zi, i = 1, ..., n, from a categorical distribution with probabilities
Pr(Zi = h | wh,Di,ηh,Σh) ∝ whchN (Di | ηh,Σh)1[0,1]m .
6. Set w′H = 1 and
(a) Draw w′h, h = 1, ...,H − 1, from Beta (1 +
∑n
i=1 1(Zi = h), α+
∑n
i=1 1(Zi > h)) .
(b) Update wh = w
′
h
∏
k<h(1− w′k).
7. Draw α from the following using a Metropolis-Hastings step
f(α | w′,Z) ∝ f(α)
H∏
h=1
Beta
(
w′h | 1 +
n∑
i=1
1(Zi = h), α+
n∑
i=1
1(Zi > h)
)
.
(a) Propose αprop from Gamma(1, 1) and accept with probability
αα =
H−1∏
h=1
Beta
(
w′h | 1 +
n∑
i=1
1(Zi = h), α
prop +
n∑
i=1
1(Zi > h)
)
H−1∏
h=1
Beta
(
w′h | 1 +
n∑
i=1
1(Zi = h), α
current +
n∑
i=1
1(Zi > h)
) .
8. Draw β(1),β(2), ...,β(K) from a Bayesian linear regression with a flat prior imposing the equality
constraints and draw the corresponding residual variances σ21Y , ..., σ
2
KY where K is the number of
treatment sequences. The posterior for β(k) is given by N (βˆ(k), σ2k(X>kXk)−1) where Xk is the design
matrix and βˆ
(k)
= (X>kXk)
−1X>k Y k. The conditional posterior will also be normal. The posterior
for σ2kY is given by Inv − χ2(s2, nk − J) where s2 = (Y k −Xkβˆ
(k)
)>(Y k −Xkβˆ(k))/(nk − J) where
J is the dimension of βˆ
(k)
.
9. Iterate until convergence.
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6 Regression model and assumptions for outcomes
6.1 Assumptions
We make the following assumption for the design of the SMART to reduce the number of relevant potential
compliances among responders and non-responders:
A.1 No cross-treatment access. Pr(DR2 = 0 | S = 0) = Pr(DNR2 = 0 | S = 1) = 1.
Assumption A.1 implies that individuals with a certain response status do not have access to the treat-
ment options under the other response status. This is a typical assumption in compliance literature that
often holds in clinical trials. Under A.1, the potential outcome of treatment sequences for responders
and non-responders are by design independent of potential compliances for non-responders (DNR21 , D
NR
22 )
and responders (DR21, D
R
22), respectively. That is E[Y | D, S = 1] = E[Y | D11, D12, DR21, DR22, S = 1],
and E[Y | D, S = 0] = E[Y | D11, D12, DNR21 , DNR22 , S = 0]. In ENGAGE, subjects who respond to
either MI-IOP or MI-PC at stage 1 (i.e., engagers) could not have received the non-responder treat-
ments. Therefore, we model responders using only the stage-1 potential compliances (D11, D12) (i.e.,
E[Y |D, S = 1] = E[Y | D11, D12, S = 1]). In addition, we assume the following:
A.2 Identifiability. For each latent compliance value in the kth treatment sequence, there is a treatment
sequence in which the corresponding compliance value is observed and its effect is identifiable.
A.3 Homogeneity. Suppose Dnm is observed in treatment sequence k and unobserved in sequence k
′, we
assume δ(D \ Dnm) = E[Yk | D, Dnm = d] − E[Yk′ | D, Dnm = d] does not depend on Dnm. The
effect of the compliance is homogeneous at least across two treatment sequences where one treatment
sequence involves the observed compliance value and other involves the latent compliance value.
A.4 Homogeneity for Stage-1 Response. Suppose Dnm is observed in treatment sequence k and unobserved
in sequence k′, we assume δS{D \ (D11, D12)} = logit Pr(S = 1 | A1 = 1, D11, D12) − logit Pr(S = 1 |
A1 = −1, D11, D12) does not depend on D11, D12. The effect of the compliance is homogeneous across
groups randomized to A1 = 1 and A1 = −1.
A.5 Ignorability of opposite branch compliance Si |= D12i | A1i = +1, D11i,X and Si |= D11i | A1i =
−1, D12i,X where X are baseline covariates.
A.6 No direct effect of stage-1 treatment on stage-2 potential compliance D2,A1,A2,S = D2,A2,S .
The compliance classes are partially latent. That is, there is no individual in the data for whom all the
compliance values are observed. This implies that the joint density of the potential compliances that is re-
quired in our Bayesian procedure is not identifiable in the absence of assumptions A.2 and A.3. Moreover, in
the conditional outcome models, the effect of unobserved compliance value is not identifiable. For example,
in ENGAGE, if we consider E[Y1 | D11, D12] = β(1)0 +β(1)1 D11 +β(1)2 D12, the parameters cannot be identified
because D12 is unobserved which also affects the convergence of the MCMC algorithm through the augmen-
tation step (i.e., step 2 in the Gibbs sampler). In fact, estimating the parameters in the outcome model
and augmenting the missing compliance values are tied together. In combination, assumptions A.2 and A.3
close this loop by equating the parameter value corresponding to a missing compliance in the outcome model
for the kth treatment sequence to the corresponding parameter value in the outcome model for another
treatment sequence in which that compliance value is observed. Although not explicitly stated, Schwartz
et al. (2011) also imposed these two identifiability assumptions in a two-arm randomized trial setting. The
following theorem formalizes the identifiability result.
Theorem 1. Assume A.2 and A.3 hold. Then, the regression coefficients for both observed and latent
potential compliances corresponding to the lth treatment sequence, β
(l)
j , are identified.
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k Treatment Sequence
Observed Potential
Compliances
Latent Potential Compliance
1 A1 = +1, S = 1 D11 NA
2 A1 = +1, S = 0, A
NR
2 = +1 D11, D22 NA
3 A1 = +1, S = 0, A
NR
2 = −1 D11 D22
4 A1 = −1, S = 1 D12 D11
5 A1 = −1, S = 0, ANR2 = +1 D12, D22 NA
6 A1 = −1, S = 0, ANR2 = −1 D12 D22
Table 3: Potential compliances modeled in each treatment sequence of the ENGAGE SMART.
6.2 ENGAGE modeling
We now specifically discuss modeling for the ENGAGE SMART. In this study, assumption A.1 is satisfied
by design. The key is to impose certain independence assumptions such that assumptions A.2 and A.3 are
satisfied. In ENGAGE, there are 3 potential compliances (D11, D12, D22). Thus a linear model including all
the main potential compliance effects are
Yk = β
(k)
0 + β
(k)
1 D11 + β
(k)
2 D12 + k, k = 1, 4
Yk = β
(k)
0 + β
(k)
1 D11 + β
(k)
2 D12 + β
(k)
3 D22 + k, k = 2, 3, 5, 6,
where k ∈ {1, 4} and k ∈ {2, 3, 5, 6} correspond to treatment sequences for responders and non-responders,
respectively and k ∼ N (0, σ2k). For responders, conditional independence between the potential outcome
and the stage-2 treatment potential compliance to which the subject was not assigned, D22 (MI-PC) holds
by design (i.e., Yik |= D22i | {D11i, D12i}, k = 1, 4). These are very general models that allow the intercepts
and main effects for each compliance values to depend on k. However, some of the parameters in these
models are not identifiable. For example, for k = 1, the compliance value D12 is unobserved and because
the effect of D12 is heterogeneous (i.e., A.2 and A.3 are violated), the parameter β
(1)
2 is not identifiable. To
make the parameters identifiable we impose some restrictions on the parametrization of these models.
Assume that the outcome model for the 1st treatment sequence is conditionally independent of D12
given D11 (i.e., Yi1 |= D12i | D11i). In addition, for non-responders to their stage-1 treatment, assume
conditional independence between the potential outcome and the opposite branch stage-1 treatment potential
compliance. Formally,
Yik |= D12i | D11i, k = 2, 3 and Yik |= D11i | D12i, k = 5, 6.
We also impose certain effect homogeneity conditions in order to identify the regression coefficients in
the outcome-potential compliance model. We set β
(4)
0 = β
(1)
0 which assumes that in the absence of any
intervention, treatment sequences 1 and 4 have the same average potential outcome. This is reasonable
because the only distinguishing feature for such subjects would be to which group they were randomized
initially. Similarly, we assume β
(3)
0 = β
(2)
0 and β
(6)
0 = β
(5)
0 . We also impose the following compliance effect
homogeneity assumptions: β
(4)
1 = β
(1)
1 ; β
(3)
3 = β
(2)
3 and β
(6)
3 = β
(5)
3 . The former implies that the rate of
change with respect to potential compliance for the outcome in treatment sequence 4 (responders to initial
treatment) as a function of MI-IOP potential compliance is the same as that in the opposite SMART branch.
The second homogeneity assumption β
(3)
3 = β
(2)
3 implies that the non-responders to stage-1 treatment MI-
IOP for the potential compliance corresponding to stage-2 MI-PC have a rate of change which is the same
between groups. The interpretation of β
(6)
3 = β
(5)
3 is similar.
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Then, the potential outcome models for responders to stage-1 treatment are
Yi1 = β
(1)
0 + β
(1)
1 D11i + 1i
Yi4 = β
(4)
0 + β
(4)
1 D11i + β
(4)
2 D12i + 4i
where ki ∼ N (0, σ2k), k = 1, 4. So, treatment sequence 1 has potential outcome which is a function of MI-
IOP potential compliance and sequence 4 has potential outcome which is also a function of stage-1 MI-PC
potential compliance.
The treatment sequences for non-engagers are
Yik = β
(k)
0 + β
(k)
1 D11i + β
(k)
3 D22i + ki, k = 2, 3 and
Yik = β
(k)
0 + β
(k)
2 D12i + β
(k)
3 D22i + ki, k = 5, 6.
where ki ∼ N (0, σ2k), k = 2, 3, 5, 6. Treatment sequences 2 and 3 are functions of the potential stage-1
MI-IOP compliance and the potential stage-2 MI-PC compliance. Furthermore, treatment sequences 5 and
6 are functions of the potential stage-1 MI-PC compliance and the potential stage-2 MI-PC compliance.
In combination the imposed restrictions lead to parameterizations of the outcome models that satisfy
assumptions A.2 and A.3. For example, β
(4)
1 is identifiable because β
(1)
1 is identifiable (A.2 is satisfied) and,
for D11, δ(D\D11) = E[Y 1 |D, D11 = d]−E[Y 4 |D, D11 = d] does not depend on D11 (i.e., A.3 is satisfied).
The identification of the other parameters follows similarly.
6.3 General modeling
Recall from Section 3 that 5 potential compliances are being modelled (D11, D12, D
R
22, D
NR
21 , D
NR
22 ). Therefore,
models for each treatment sequence potential outcomes would be
Yk = β
(k)
0 + β
(k)
1 D11 + β
(k)
5 D12 + β
(k)
2 D
R
22 + k, k = 1, 2, 5, 6
Yk = β
(k)
0 + β
(k)
1 D11 + β
(k)
5 D12 + β
(k)
3 D
NR
21 + β
(k)
4 D
NR
22 + k, k = 3, 4, 7, 8,
where k ∈ {1, 2, 5, 6} and k ∈ {3, 4, 7, 8} correspond to treatment sequences for responders and non-
responders, respectively and ki ∼ N (0, σ2k), k = 1, ..., 8.
Assumption A.1 holds by design just as in ENGAGE. We impose independence assumptions so that A.2
and A.3 hold. For responders, we have conditional independence between the potential outcomes and stage-2
potential compliance corresponding to treatments the subject was not assigned DNR21 , D
NR
22 by design:
Yi1 |= {DNR21i , DNR22i } | D11i Yi5 |= {DNR21i , DNR22i } | D12i
Yi2 |= {DNR21i , DNR22i } | D11i, DR22i Yi6 |= {DNR21i , DNR22i } | D12i, DR22i
Similarly, for non-responders, DR22i:
Yi3 |= DR22i | D11i, DNR21i Yi7 |= DR22i | D12i, DNR22i
Yi4 |= DR22i | D11i, DNR21i , DNR22i Yi8 |= DR22i | D12i, DNR21i , DNR22i
Without imposing identifiability constraints, the assumptions A.2 and A.3 will be violated and regression
coefficients will not be identifiable. Assume the following conditional independence conditions between the
potential outcomes and the potential compliances:
Yi1 |= {DR22i, D12i} | D11i Yi5 |= {D11i, DNR21i , DNR22i } | D12i
Yi2 |= D12i | D11i, DR22i Yi6 |= D11i | D12i, DR22i
Yi3 |= {DNR22i , D12i} | D11i, DNR21i Yi7 |= {D11i, DNR22i } | D12i, DNR21i
Yi4 |= D12i | D11i, DNR21i , DNR22i Yi8 |= D11i | D12i, DNR21i , DNR22i .
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k Treatment Sequence
Observed Potential
Compliances
Latent Potential Compliance
1 A1 = +1, S = 1, A
R
2 = +1 D11 NA
2 A1 = +1, S = 1, A
R
2 = −1 D11, DR22 NA
3 A1 = +1, S = 0, A
NR
2 = +1 D11, D
NR
21 NA
4 A1 = +1, S = 0, A
NR
2 = −1 D11, DNR22 DNR21
5 A1 = −1, S = 1, AR2 = +1 D12 NA
6 A1 = −1, S = 1, AR2 = −1 D12, DR22 NA
7 A1 = −1, S = 0, ANR2 = +1 D12, DNR21 NA
8 A1 = −1, S = 0, ANR2 = −1 D12, DNR22 DNR21
Table 4: Potential compliances modeled in each treatment sequence of the General SMART.
We impose the following homogeneity constraints in order to identify the regression coefficients: we set
β
(4)
0 = β
(3)
0 which assumes in the absence of any intervention, treatment sequences 3 and 4 have the same
average potential outcome. This is reasonable because the only distinguishing feature for such subjects
would be to which group they were randomized intially. Similarly, β
(8)
0 = β
(7)
0 . We also impose the following
compliance effect homogeneity assumptions: β
(4)
1 = β
(3)
1 ; β
(8)
5 = β
(7)
5 ; β
(4)
3 = β
(3)
3 and β
(8)
3 = β
(7)
3 . These
consrtaints imply that the rate of change with respect to a particular potential compliance for a given
treatment sequence as a function of the potential compliance is the same as in another treatment sequence.
The identifiability constraints guarantee that A.2 and A.3 hold.
Our assumptions imply the following potential outcome models:
Y1 = β
(1)
0 + β
(1)
1 D11 + 1 Y5 = β
(5)
0 + β
(5)
5 D12 + 5
Y2 = β
(2)
0 + β
(2)
1 D11 + β
(2)
2 D
R
22 + 2 Y6 = β
(6)
0 + β
(6)
5 D12 + β
(6)
2 D
R
22 + 6
Y3 = β
(3)
0 + β
(3)
1 D11 + β
(3)
3 D
NR
21 + 3 Y7 = β
(7)
0 + β
(7)
5 D12 + β
(7)
3 D
NR
21 + 7
Y4 = β
(4)
0 + β
(4)
1 D11 + β
(4)
3 D
NR
21 + β
(4)
4 D
NR
22 + 4 Y8 = β
(8)
0 + β
(8)
5 D12 + β
(8)
3 D
NR
21 + β
(8)
4 D
NR
22 + 8
where ki ∼ N (0, σ2k), k = 1, ..., 8. Assumptions A.2 and A.3 are satisfied, so by Theorem 1, the coefficients
in the above models are identified. We have described how to model E[Y | A1 = a1, S,A2 = a2,D]. Next,
we describe how to model Pr(S = 1 | A1 = a1,D) so that we can estimate the principal causal effects.
6.4 Stage-1 response indicator model
We assume A.4 holds. We model the probability of response in each branch using Bayesian logistic regression
with a flat prior on γ:
Pr(S = 1 | A1 = a1j , D11, D12) = expit{(1, D11, D12, a1j)>γ}
where expit(·) = exp(·)
1 + exp(·) . In particular, the posterior of γ is proportional to the following:
n∏
i=1
[
expit{(1, D11i, D12i, a1ji)>γ}
]Si [
1− expit{(1, D11i, D12i, a1ji)>γ}
]1−Si
We draw from the posterior using Metropolis-Hastings (Hastings, 1970). We simulate 10000 draws and
consider every 10th draw. Under assumption A.4, the parameter γ can be identified. Alternatively, one
could assume A.5 in which case the model would omit one of the D1j ’s and model each treatment sequence
A1 = −1 and A1 = +1 separately.
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7 Model selection
We perform model selection using the Watanabe–Akaike information criterion (Gelman et al., 2013). This
information criterion aims to estimate the expected log pointwise predictive density (elppd) for a new data
set with n points which is given by
elppd =
n∑
i=1
Ey˜i [log p(y˜i | y)]
=
n∑
i=1
Ey˜i
[
log
∫
p(y˜i | θ)p(θ | y)dθ
]
=
n∑
i=1
∫ [
log
∫
p(y˜i | θ)p(θ | y)dθ
]
p(y˜i)dy˜i
where p(y˜i) is the marginal distribution of each data point and y is the observed data. Watanabe–Akaike
information criterion averages over the posterior distribution instead of conditioning on, for example, the
posterior mean. It is estimating the average log predictive density for a new data set as opposed to just a
single point. It is a fully Bayesian information criterion in that it uses the posterior distribution.
We treat the imputed potential compliances as parameters. The Watanabe–Akaike information criterion
assesses the predictive accuracy of the model applied to new data given the observed data and penalizes
for model complexity as a bias correction. An estimate of the information criterion (WAIC) for treatment
sequence j is given as follows (Gelman et al., 2013):
ŴAIC = −2
nj∑
i=1
log
{
1
K
K∑
k=1
f(Yi |Dobs,D(k)mis,β(k)j , σ2,(k)j )
}
+ 2
nj∑
i=1
V̂arDmis,βj ,σ2j
[
log
{
f
(
Yi |Dobs,Dmis,βj , σ2j
)}]
.
The expression has a factor of −2 so that it is on the deviance scale. Lower values of the information
criterion indicate better model fit.
8 Multiple comparisons with the best
Our goal is to identify the embedded DTRs with the greatest efficacy incorporating compliance class. Multiple
comparisons with the best (MCB) provides clinicians with a way to interpret compliance classes’ impact on
outcomes. It provides inference for the optimal embedded DTRs under varying levels of compliance. MCB
was leveraged in the SMART setting in Ertefaie et al. (2015); Artman et al. (2018). MCB was based off a
normal parametric model in the frequentist setting. Below, we describe an extension to the Bayesian setting
which is calculated using draws from the posterior.
MCB entails constructing simultaneous one-sided upper credible limits for the difference between each
embedded DTR and the optimal embedded DTR. Here, the Bonferroni correction was used to construct
95% credible intervals which control the false positive rate. When choosing an embedded DTR from the
set of best, it makes sense to also consider side-effect profiles. With MCB, one may offer a set of optimal
embedded DTRs which are not statistically distinguishable from the best for the given data. Consequently,
it allows the clinician to choose an optimal embedded DTR which takes into account cost and side-effect
burden known externally from the study. We apply the method to four different compliance classes as well
as the intention-to-treat group. If the interval covers zero, it is statistically indistinguishable from the best.
If it does not cover zero, it is excluded from the set of best (optimal embedded DTRs, Bˆ below).
The goal of MCB is to construct a set of optimal embedded DTRs as a function of compliance class. The
set of best is defined as follows:
Bˆ = {EDTRl | EDTRl is not statistically distinguishable from the best EDTR at level α}.
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Bias (Standard Errors) for Main Effects Only Model
Correlation = 0.2
Par. Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
β0 0.00 (0.05) 0.01 (0.06) 0.01 (0.06) 0.00 (0.05) 0.00 (0.05) 0.00 (0.05)
β1 0.00 (0.08) 0.01 (0.09) 0.01 (0.13) 0.00 (0.08) – (–) – (–)
β2 – (–) – (–) – (–) 0.04 (0.07) 0.00 (0.07) 0.00 (0.10)
β3 – (–) 0.00 (0.08) 0.00 (0.08) – (–) 0.01 (0.07) 0.01 (0.07)
Correlation = 0.5
Par. Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
β0 0.00 (0.05) 0.01 (0.06) 0.01 (0.06) 0.00 (0.05) 0.00 (0.05) 0.00 (0.05)
β1 0.00 (0.08) 0.01 (0.10) 0.01 (0.14) 0.00 (0.08) – (–) – (–)
β2 – (–) – (–) – (–) 0.07 (0.08) 0.01 (0.07) 0.01 (0.10)
β3 – (–) 0.00 (0.09) 0.00 (0.09) – (–) 0.01 (0.09) 0.01 (0.09)
Correlation = 0.8
Par. Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
β0 0.00 (0.05) 0.01 (0.06) 0.01 (0.06) 0.00 (0.05) 0.00 (0.05) 0.00 (0.05)
β1 0.00 (0.08) 0.01 (0.14) 0.04 (0.19) 0.00 (0.08) – (–) – (–)
β2 – (–) – (–) – (–) 0.10 (0.08) 0.01 (0.10) 0.04 (0.12)
β3 – (–) 0.00 (0.13) 0.00 (0.13) – (–) 0.01 (0.12) 0.01 (0.12)
Table 5: ENGAGE simulation results for main effects only model with n = 250 sample size and approxi-
mately 200 replicates. β0 is the intercept; β1 is the coefficient corresponding to D11 (stage-1 MI-IOP); β2 is
the coefficient corresponding to D12 (stage-1 MI-PC); and β3 is the coefficient corresponding to D22 (stage-2
MI-PC). – = not part of model.
To construct such a set, we compare each embedded DTR to the best embedded DTR by constructing
one-sided upper credible intervals adjusting for multiplicity. In particular, simultaneous credible intervals for
Y (l) −maxl′ Y (l′). Let Ul denote the upper limit of the lth credible interval. Then, Bˆ = {EDTRl | Ul ≥ 0}.
The embedded DTRs not contained in Bˆ are significantly inferior to the optimal embedded DTR. An
advantage of MCB is that it entails only L−1 comparisons where L is the number of embedded DTRs. This
may be substantially less than all pairwise comparisons.
We construct U1, ..., UL−1 from the MCMC draws of Y (l), l = 1, ..., L by taking the 1 − α/(L − 1)
quantile of each of the draws minus the best embedded DTR outcome draw. This controls the type I error
rate of excluding the true best embedded DTR. This can be done for each compliance class Cb yielding
Bˆ(C1), Bˆ(C2), ..., Bˆ(CB). The embedded DTRs which are included in all plausible compliance class are a good
choice for patients whose potential compliance class is unknown. Given information about what compliance
class a patient will likely belong to determines which set of best embedded DTRs is optimal and subsequently,
which embedded DTRs are optimal.
9 Simulation study
We simulated two SMARTs with the same structure as ENGAGE and the General SMART design, respec-
tively with a sample size of n = 250.
9.1 ENGAGE simulation
Here, we summarize the ENGAGE SMART simulation.
The potential compliances were generated from a Gaussian copula model using the R package copula.
This model is fully specified by the marginal distributions and the correlation matrix of the potential com-
pliances. We use Beta distributed margins such that the parameters for the stage-1 compliance are (3, 2),
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(2, 1), and the stage-2 compliance is (2, 3). The correlation matrix was
R =
1 ρ ρρ 1 ρ
ρ ρ 1

for ρ = 0.2, 0.5, 0.8. We generated stage-1 response indicators as Si ∼ Bern
{
exp(D11 − 1)
1 + exp(D11 − 1)
}
when
A1i = +1 and Si ∼ Bern
{
exp(D12 − 1.5)
1 + exp(D12 − 1.5)
}
when A1i = −1. The following potential outcome models
were generated for each of the 6 treatment sequences embedded in the SMART.
Yi1 = 0.7 + 0.6D11i + 1i Yi4 = 0.7 + 0.6D11i + 0.6D12i + 4i
Yi2 = 0.2 + 0.7D11i + 0.9D22i + 2i Yi5 = 0.3 + 0.6D12i + 0.7D22i + 5i
Yi3 = 0.2 + 0.6D11i + 0.9D22i + 3i Yi6 = 0.3 + 0.6D12i + 0.7D22i + 6i
where ki
iid∼ N (0, 0.12). The embedded DTR regression coefficient results are summarized in Table 5. In
particular, note that the estimates are nearly unbiased across correlations. Furthermore, the standard errors
are small even for the high correlation scenario. The bias and standard errors are slightly higher, but still
reasonable when the correlation between potential compliance is 0.8.
We compare the main effects model fit with the interaction model fit for the following treatment sequence
outcomes:
Yi1 = 0.7 + 0.6D11i + 1i Yi4 = 0.7 + 0.6D11i + 0.6D12i + 4i
Yi2 = 0.2 + 0.7D11i + 0.9D22i + 2.0D11iD22i + 2i Yi5 = 0.3 + 0.6D12i + 0.7D22i + 1.5D12iD22i + 5i
Yi3 = 0.2 + 0.6D11i + 0.9D22i + 2.0D11iD22i + 3i Yi6 = 0.3 + 0.6D12i + 0.7D22i + 1.5D12iD22i + 6i
where ki ∼ N (0, σ2k), k = 1, ..., 6. We impose the additional equality constraints that β(3)4 = β(2)4 and
β
(6)
4 = β
(5)
4 for the interaction model. The results are summarized in Table 6. The standard errors are
inflated due to collinearity induced by including the interaction terms. However, the results have low bias.
Note that the Watanabe–Akaike information criterion is lower for the interaction fit when the true model
is the interaction model (see Table 8). However, for treatment sequence 3, the model’s Watanabe–Akaike
information criterion is only slightly lower for the interaction model.
9.2 General SMART Study
Next, we summarize the general SMART (see Figure 2 for the study design). This SMART has the most
general structure of SMART designs we consider in this article. Individuals are initially randomized to
Treatments (Trt.) 1 and 2. After the a set period of time (e.g., 2 weeks), subjects are subsequently
monitored weekly for non-response to determine stage-2 treatments.
If a subject is classified as a non-responder, they move to stage 2 and are re randomized to one of
two treatments: switch from Trt. 1 (or 2) to Trt. 4 or add Trt. 4 to Trt. 1 (or 2). At week 8, for
example, individuals who do not meet their assigned non-response criterion are considered responders and
re-randomized to one of two interventions: add Trt. 3 to Trt. 1 (or 2) or continue Trt. 1 (or 2) alone.
We model 5 potential compliances in the General SMART corresponding to the following interventions:
Trt. 1, Trt. 2, Trt. 1+Trt 3 or Trt 2 + Trt 3, Trt 1+Trt 4 or Trt 2+Trt 4, Trt 4. There are a total of
8 treatment sequences and 8 embedded DTRs. For example, one of the embedded DTRs is given by the
following decision rules: start the treatment with Trt. 1. If an individual becomes a non-responder, add Trt.
4; if at week 8 the individual is classified as a responder, add Trt. 3. See Table 2 for the other embedded
DTRs.
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Bias (Standard Errors) for Interaction Model
Correlation = 0.2
Par. Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
β0 0.00 (0.06) 0.01 (0.12) 0.01 (0.12) 0 (0.06) 0.02 (0.11) 0.02 (0.11)
β1 0.00 (0.09) 0.02 (0.2) 0.00 (0.35) 0.00 (0.09) – (–) – (–)
β2 – (–) – (–) – (–) 0.04 (0.07) 0.02 (0.17) 0.06 (0.28)
β3 – (–) 0.01 (0.29) 0.01 (0.29) – (–) 0.06 (0.29) 0.06 (0.29)
β13 – (–) 0.02 (0.45) 0.02 (0.45) – (–) – (–) – (–)
β23 – (–) – (–) – (–) – (–) 0.07 (0.42) 0.07 (0.42)
Correlation = 0.5
Par. Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
β0 0.00 (0.06) 0.01 (0.11) 0.01 (0.11) 0.00 (0.06) 0.01 (0.11) 0.01 (0.11)
β1 0.01 (0.09) 0.02 (0.19) 0.04 (0.39) 0.01 (0.09) – (–) – (–)
β2 – (–) – (–) – (–) 0.07 (0.09) 0.01 (0.17) 0.08 (0.28)
β3 – (–) 0.01 (0.28) 0.01 (0.28) – (–) 0.06 (0.32) 0.06 (0.32)
β13 – (–) 0.02 (0.43) 0.02 (0.43) – (–) – (–) – (–)
β23 – (–) – (–) – (–) – (–) 0.06 (0.44) 0.06 (0.44)
Correlation = 0.8
Par. Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
β0 0.00 (0.06) 0.01 (0.10) 0.01 (0.10) 0.00 (0.06) 0.01 (0.10) 0.01 (0.10)
β1 0.01 (0.09) 0.02 (0.18) 0.02 (0.41) 0.01 (0.09) – (–) – (–)
β2 – (–) – (–) – (–) 0.09 (0.07) 0.00 (0.16) 0.09 (0.29)
β3 – (–) 0.01 (0.30) 0.01 (0.30) – (–) 0.07 (0.38) 0.07 (0.38)
β13 – (–) 0.01 (0.40) 0.01 (0.40) – (–) – (–) – (–)
β23 – (–) – (–) – (–) – (–) 0.06 (0.46) 0.06 (0.46)
Table 6: ENGAGE interaction model simulation results for n = 250 sample size and approximately
200 replicates. β0 is the intercept; β1 is the coefficient corresponding to D11 (stage-1 MI-IOP); β2 is the
coefficient corresponding to D12 (stage-1 MI-PC); β3 is the coefficient corresponding to D22; β13 is the
coefficient corresponding to the interaction between D11 and D22; and β23 is the coefficient corresponding
to the interaction between D12 and D22 (stage-2 MI-PC). – = not part of model.
9.3 General SMART simulation
The potential compliances were generated from a Gaussian copula model using the R package copula. This
model is fully specified by the margins and correlation matrix. We use Beta distributed margins such that the
parameters for the stage-1 compliances are (3, 2) and the stage-2 compliances are (2, 1), (2, 3), (2, 1), (3, 2).
The correlation between potential compliances was set to 0.2. We generated stage-1 response indicators as
Si ∼ Bern
{
exp(D11 − 1)
1 + exp(D11 − 1)
}
when A1i = +1 and Si ∼ Bern
{
exp(D12 − 1.5)
1 + exp(D12 − 1.5)
}
when A1i = −1. The
following potential outcome models were generated for each of the 6 treatment sequences embedded in the
SMART.
Yi1 = 1.0 + 0.6D11i + 1i Yi5 = 0.7 + 0.6D12i + 5i
Yi2 = 0.4 + 0.5D11i + 0.8D
R
22i + 2i Yi6 = 0.6 + 0.2D12i + 0.4D
R
22i + 6i
Yi3 = 0.2 + 0.8D11i + 0.9D
NR
21i + 3i Yi7 = 0.4 + 0.5D12i + 0.9D
NR
21i + 7i
Yi4 = 0.2 + 0.8D11i + 0.9D
NR
21i + 0.7D
NR
22i + 4i Yi8 = 0.4 + 0.5D12i + 0.9D
NR
21i + 0.7D
NR
22i + 8i
where ki
iid∼ N (0, 0.12). The results are summarized in Table 7. Similarly to the ENGAGE simulation, the
results for EXTEND indicate low bias and standard errors. The low standard errors is despite there being
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Bias (Standard Errors) for Main Effects Model
Correlation = 0.2
Par. Seq. 1 Seq. 2 Seq. 3 Seq. 4 Seq. 5 Seq. 6 Seq. 7 Seq. 8
β0 0.01 (0.07) 0.01 (0.09) 0.00 (0.06) 0.00 (0.06) 0.02 (0.09) 0.00 (0.12) 0.00 (0.05) 0.00 (0.05)
β1 0.01 (0.10) 0.01 (0.11) 0.00 (0.09) 0.00 (0.09) – (–) – (–) – (–) – (–)
β2 – (–) 0.00 (0.09) – (–) – (–) – (–) 0.00 (0.12) 0.00 (0.08) – (–)
β3 – (–) – (–) 0.01 (0.09) 0.01 (0.09) – (–) – (–) – (–) 0.00 (0.08)
β4 – (–) – (–) – (–) 0.01 (0.14) – (–) – (–) – (–) 0.01 (0.14)
β5 0.00 (0.07) – (–) – (–) – (–) 0.02 (0.14) 0.00 (0.15) 0.00 (0.08) 0.00 (0.08)
Table 7: General SMART simulation results for main effects only model with n = 250 sample size and
approximately 200 replicates for General. – = not part of model.
fewer subjects in each of the treatment sequences when compared with ENGAGE.
10 Real data application: ENGAGE study
We have assessed the performance of our method on simulated versions of the ENGAGE study. Now, we
apply our methodology to the real data in order to determine which EDTRs are optimal across compliance
classes. Since the data is longitudinal, we define our outcome as the log of the sum of days from weeks 2
to 24 in which alcohol was consumed and the sum of the days cocaine was consumed plus a small positive
constant. We consider only African-Americans who did not engage by week 2. We fit the same models as in
the simulation studies. We do not incorporate covariates besides potential compliances in our analysis.
In Figure 6, we apply MCB. Within each compliance class the median compliance in the quantile interval is
chosen for each potential compliance. Intention-to-treat analysis was carried out using a marginal structural
model (Nahum-Shani et al., 2012). Confidence intervals were constructed for the MSM using the bootstrap.
We see that for all the compliance classes, embedded DTRs 1 and 2 are optimal. For compliance classes
75%-100%, 100%, and intention-to-treat (ITT), 3 and 4 are significantly inferior to the optimal embedded
DTR. In 25%-50% and 50%-75%, all embedded DTRs are optimal. Although not statistically significant,
the embedded DTR in which patients receive NFC is more efficacious than subjects who receive MI-PC in
intention-to treat.
In Figure 7, potential compliances in ENGAGE, D11, D12, D22 are plotted with outcome indicated by
shade. Lighter shades indicate more favorable outcomes. Note that as the potential compliances vary
between 0 and 1, the probability of stage-1 response changes which affects how much weight each treatment
sequence outcome contributes to the embedded DTR outcomes. This may make it so that the outcome is
not strictly monotone in a potential compliance. Note that these plots suggest optimal embedded DTRs
consist of MI-IOP in stage-1.
In Table 10, we have point estimates and corresponding standard errors listed for each of the potential
compliance regression coefficients. In Table 12, we have the individual treatment sequence point estimates
and standard errors. We first summarize the main effects model. We see that for all treatment sequences
higher first stage compliance leads to less days consuming alcohol/cocaine. For treatment sequences 2 and 3,
there is some evidence that stage-2 potential compliance leads to better outcomes. For treatment sequences 5
and 6, higher potential compliances in stage 2 are associated with poor outcomes, but the standard errors for
the corresponding coefficients are large. The interpretation of the interaction model may proceed similarly.
However, despite the large negative interaction terms, the large standard error complicates the interpretation.
In Table 13, we see that the Watanabe-Akaike information criterion suggests the Main Effects model is a
better fit than the interaction model as it has lower information criterion values.
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Watanabe–Akaike information criterion for Simulated ENGAGE
Model Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
Main Effects -80.63 -44.28 32.32 -38.88 516.80 555.14
Interaction -80.51 -61.57 30.91 -38.38 9.45 358.10
Table 8: Watanabe–Akaike information criterion also known as the widely applicable information criterion
for each treatment sequence in the simulated ENGAGE SMART for the main effects only model and the
interaction model. The results are averaged across approximately 200 simulation replicates.
11 Discussion
Compliance is an important predictor of outcomes for substance use disorders commonly studied in SMARTs.
In this paper, we fill the methodological gap in accounting for partial compliance in the SMART setting.
Adjusting for partial as opposed to binary compliance allows for more flexibility when there is continuous
compliance and the threshold for compliers vs. non-compliers is not easily determined. Challenges in adjust-
ing for compliance include the post-treatment adjustment bias for observed compliances, and assumptions
which must be imposed for identifiability. We presented sufficient conditions for identifiability of the para-
metric regression model. We extend the methodology in Schwartz et al. (2011) from single-stage decision
to multi-stage decision settings, so that the embedded DTRs outcomes may be determined as a function of
partial compliance. We applied a semiparametric Bayesian model for principal stratification to determine
the optimal embedded DTR for a given compliance class.
When choosing an optimal embedded DTR from the set of best constructed using MCB, one can use
information about the compliance of a patient. If such information is not known, choosing a DTR which
is in the set of best across a plausible range of compliance classes is reasonable. An alternative approach
is to use demographic information to predict how compliant a patient will likely be; hence, which DTR is
optimal. For example, one could consider whether a patient’s age falls in a specific window.
The method leverages a non-parametric Dirichlet process mixture for kernel density estimation of the joint
potential compliance distribution allowing for complex but realistic compliance distributions to be modeled.
It does not require arbitrary dichotomization as it models partial compliance as a continuous variable between
0 and 1 which is particularly useful and realistic for conditions studied in SMARTs. Principal stratification
elucidates the effect of compliance on outcomes and avoids the problem of adjusting for observed compliances
which are post-treatment variables. Furthermore, we showed how MCB may be implemented in the Bayesian
setting and how to apply it to construct sets of best embedded DTRs within compliance classes.
Previous work in two-arm clinical trials have failed to validate their method either analytically or through
simulation. We demonstrated the validity of our method both mathematically and through extensive simu-
lation studies for varying degrees of correlation between the potential compliances. While we focused on a
two-stage SMART with at most two different interventions at each stage of randomization, the method may
be extended to SMARTs with a greater number of potential compliances.
One of the major challenges with principal stratification, is that some of the potential compliances are
latent. This is handled via data augmentation. By making identifiability assumptions similar to Schwartz
et al. (2011), we were able to achieve low bias and small standard errors. Future work should entail tailoring
treatments according to compliance using Q-learning and relaxing the linearity assumption in the outcome-
compliance model. An alternative approach which still uses principal stratification would be to model each
embedded DTR directly rather than each treatment sequence. The pitfall for such an approach is it would not
allow as much flexibility when defining the identifiability constraints for the regression coefficients. If we could
observe the potential compliances, then modeling the embedded DTRs directly would be straightforward
using a weighted and replicated linear regression. However, some potential compliances are missing. Since
the pattern of missingness is at the level of treatment sequence rather than embedded DTR, imputation of
missing compliances is made more difficult with direct modeling.
Another important extension to the proposed method would be to account for partial or binary compliance
in a way that fully accounts for the often longitudinal nature of compliance.
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Mean Embedded DTR Outcomes (Standard Errors) for Main Effects Model (Simulated)
Compliance Class EDTR 1 EDTR 2 EDTR 3 EDTR 4 Set of Best (Bˆ)
25%-50% 1.10 (0.01) 1.17 (0.04) 1.21 (0.01) 1.26 (0.03) EDTR 1, EDTR 2
50%-75% 1.45 (0.04) 1.53 (0.05) 1.59 (0.01) 1.65 (0.02) EDTR 1
75%-100% 1.79 (0.11) 1.87 (0.13) 2.00 (0.02) 2.06 (0.04) EDTR 1, EDTR 3
100% 2.15 (0.26) 2.21 (0.29) 2.53 (0.08) 2.59 (0.09) EDTR 1, EDTR 3, EDTR 4
ITT 1.19 (0.05) 1.20 (0.05) 1.37 (0.04) 1.38 (0.05) EDTR 1, EDTR 2
Table 9: Simulated ENGAGE SMART main effects only model EDTR point estimates by compliance class.
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Point Estimates (Standard Errors) for Main Effects Model
Par. Seq. 1 Seq. 2 Seq. 3 Seq. 4 Seq. 5 Seq. 6
β0 2.66 (0.44) 2.77 (0.86) 2.77 (0.86) 2.66 (0.44) 3.49 (0.46) 3.49 (0.46)
β1 -2.76 (0.75) 0.06 (1.78) -2.43 (3.05) -2.76 (0.75) – (–) – (–)
β2 – (–) – (–) – (–) -0.35 (1.16) -1.61 (1.68) -4.46 (2.67)
β3 – (–) -2.16 (2.11) -2.16 (2.11) – (–) 0.82 (0.98) 0.82 (0.98)
Point Estimates (Standard Errors) for Interaction Model
Par. Seq. 1 Seq. 2 Seq. 3 Seq. 4 Seq. 5 Seq. 6
β0 2.67 (0.44) 3.01 (1.00) 3.01 (1.00) 2.67 (0.44) 3.57 (0.61) 3.57 (0.61)
β1 -2.78 (0.75) -0.64 (2.3) -2.7 (4.28) -2.78 (0.75) – (–) – (–)
β2 – (–) – (–) – (–) 0.37 (0.72) -2.28 (3.16) -5.74 (3.82)
β3 – (–) -4.23 (4.13) -4.23 (4.13) – (–) 0.54 (1.43) 0.54 (1.43)
β13 – (–) 5.95 (9.82) 5.95 (9.82) – (–) – (–) – (–)
β23 – (–) – (–) – (–) – (–) 1.33 (4.53) 1.33 (4.53)
Table 10: Real data illustration: ENGAGE SMART. – = not part of model.
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Figure 6: MCB applied to the real ENGAGE SMART. See Table 1 for a legend of embedded DTRs. EDTR
= embedded DTR, ITT = intention-to-treat. Simultaneous upper one-sided credible intervals by compliance
class for the difference between each EDTR and the optimal embedded DTR. ITT are confidence intervals
computed using the bootstrap.
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Figure 7: Real ENGAGE SMART. 3D representation of 4D surface by potential compliance plots. The shade
represents the log of the sum of the number of days drinking alcohol and the number of days consuming
cocaine. Lighter shades are more favorable.
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Mean Embedded DTR Outcomes (Standard Errors) for Main Effects Model: General SMART
Compliance
Class
EDTR 1 EDTR 2 EDTR 3 EDTR 4 EDTR 5 EDTR 6 EDTR 7 EDTR 8 Set of Best (Bˆ)
25%-50% 1.05 (0.03) 1.27 (0.02) 0.99 (0.02) 1.22 (0.02) 0.96 (0.01) 1.31 (0.02) 0.94 (0.01) 1.29 (0.02) EDTRs 3, 5, 7
50%-75% 1.26 (0.02) 1.56 (0.02) 1.24 (0.02) 1.54 (0.03) 1.15 (0.01) 1.58 (0.03) 1.14 (0.02) 1.57 (0.04) EDTRs 5, 7
75%-100% 1.52 (0.02) 1.90 (0.05) 1.52 (0.02) 1.90 (0.05) 1.37 (0.02) 1.87 (0.07) 1.37 (0.02) 1.87 (0.07) EDTRs 5,7
100% 1.87 (0.04) 2.30 (0.10) 1.86 (0.04) 2.29 (0.11) 1.62 (0.05) 2.14 (0.12) 1.63 (0.05) 2.15 (0.12) EDTRs 5, 7
ITT 1.31 (0.04) 1.27 (0.04) 1.29 (0.04) 1.25 (0.04) 1.18 (0.04) 1.14 (0.04) 1.16 (0.03) 1.12 (0.03) EDTRs 5, 6 ,7,8
Table 11: Simulated general SMART main effects only model EDTR point estimates by compliance class.
Mean Embedded DTR Outcomes (Standard Errors) for Main Effects Model
Compliance Class EDTR 1 EDTR 2 EDTR 3 EDTR 4 Set of Best (Bˆ)
25%-50% 2.52 (0.14) 2.51 (0.48) 3.09 (0.36) 2.48 (0.48) EDTRs 1, 2, 3, and 4
50%-75% 1.95 (0.29) 1.95 (0.31) 2.31 (0.08) 2.10 (0.12) EDTRs 1, 2, 3, and 4
75%-100% 0.50 (0.28) 0.50 (0.28) 1.57 (0.05) 1.54 (0.05) EDTR 1, EDTR 2
100% -0.18 (0.26) -0.18 (0.27) 1.45 (0.05) 1.44 (0.05) EDTR 1, EDTR 2
ITT 2.02 (0.26) 1.73 (0.25) 2.88 (0.22) 2.59 (0.22) EDTR 1, EDTR 2
Table 12: Real ENGAGE SMART main effects only model EDTR point estimates by compliance class.
Real Data Illustration: Watanabe–Akaike information criterion
Model Trt. Seq. 1 Trt. Seq. 2 Trt. Seq. 3 Trt. Seq. 4 Trt. Seq. 5 Trt. Seq. 6
Main Effects 92.47 79.64 84.82 149.78 59.77 74.15
Interaction 92.59 82.71 86.35 148.30 63.66 74.45
Table 13: Watanabe–Akaike information criterion for each treatment sequence in the real ENGAGE SMART
for the main effects only model and the interaction model.
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Appendix A: Representation of the PCE
PCE(l)(D) = E[Y (l) |D]
= E[Y | EDTRl,D]
= E[Y | A1 = a1l,EDTRl,D]
= E[Y | A1 = a1l, S = 1,EDTRl,D] Pr(S = 1 | A1 = a1l,EDTRl,D)
+ E[Y | A1 = a1l, S = 0,EDTRl,D] Pr(S = 0 | A1 = a1l,EDTRl,D)
= E[Y | A1 = a1l, S = 1,D] Pr(S = 1 | A1 = a1l,D)
+ E[Y | A1 = a1l, S = 0, ANR2 = a2l,D] Pr(S = 0 | A1 = a1l,D)
where EDTRl is the l
th embedded DTR.
28
Appendix B: Identification of Regression Coefficients
Without loss of generality, we prove identifiability for a specific treatment sequences in the ENGAGE SMART
for illustration. Treatment sequences 1, 2, and 5 are fully observable so the regression coefficients are
identified.
Consider the model for treatment sequence 4:
Y4 = β
(4)
0 + β
(4)
1 D11 + β
(4)
2 D12.
Suppose assumptions A.2 (identifiability) and A.3 (homogeneity) hold. Then, β
(4)
0 = β
(1)
0 and β
(4)
1 = β
(1)
1 .
We will show that the coefficient corresponding to the observed compliance, β
(4)
2 , is identified. LetXc denote
the true design matrix and X denote the design matrix that was imputed using data augmentation.
Write the true model in matrix notation as
E[Y |Xc] = Xcβ(4)
We have that
βˆ
(4)
= (X>X)−1X>Y ⇒ (3)
X>Xβˆ
(4)
= X>Y (4)
= X>Xcβ(4)
Note that
e1X
>X =
(
1>1 1>D˜11 1>D12
)
where D˜11 denotes an imputed potential compliance.
and
e1X
>Xc =
(
1>1 1>D11 1>D12
)
(5)
where
e1 =
(
1 0 0
)
(6)
Hence,
1>1βˆ(4)0 + 1
>D˜11βˆ
(4)
1 + 1
>D12βˆ
(4)
2 = 1
>1β(4)0 + 1
>D11β
(4)
1 + 1
>D12β
(4)
2
by equations 6, 7, and 8. Then, take the conditional expectation of both sides conditioning on D12, βˆ
(4)
0 =
β
(1)
0 , βˆ
(4)
1 = β
(1)
1 , and the treatment sequence potential outcome Y4.
1>1E[βˆ(4)0 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4]
+ 1>E[D˜11βˆ(4)1 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4]
+ 1>D12E[βˆ(4)2 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4] = 1>1β(1)0 + 1>D11β(1)1 + 1>D12β(4)2
Hence,
1>1β(1)0
+ 1>β(1)1 E[D˜11 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4]
+ 1>D12E[βˆ(4)2 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4]
= 1>1β(1)0 + 1
>D11β
(1)
1 + 1
>D12β
(4)
2
where we have used the identifiability constraints βˆ
(4)
0 = β
(1)
0 and βˆ
(4)
1 = β
(1)
1 .
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Rearranging yields:
E[βˆ(4)2 − β(4)2 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4]
= β
(1)
1
1>
1>D12
(
E[D11 |D12]− E[D˜11 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4]
)
Then,
E[D11 |D12]− E[D˜11 |D12, βˆ(4)0 = β(1)0 , βˆ(4)1 = β(1)1 , Y4] = 0
using well-known facts about the conditional distribution of multivariate normal distributions.
Hence, βˆ
(4)
2 is unbiased for β
(4)
2 .
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11.1 Appendix C: Plots for simulation
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Figure 8: EDTR = embedded DTR, ITT = intention-to-treat. Simultaneous upper one-sided credible
intervals by compliance class for the difference between each EDTR and the optimal embedded DTR for
main-effects models. Top graph: simulated ENGAGE SMART.Lower graph: general SMART simulation.
ITT are confidence intervals computed using the bootstrap.
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